Ace-031

Overview

ACE-031 is a soluble fusion protein engineered from the activin receptor type IIB (ActRIIB). It works by intercepting myostatin and other natural inhibitors of muscle growth, releasing skeletal muscle from the signals that normally limit how big it can get. The compound was originally pursued as a treatment for muscle-wasting diseases, most notably Duchenne muscular dystrophy (DMD). Like most peptides circulating in the research-chemical market, it is supplied as a powder that requires reconstitution and subcutaneous injection, and purity plus proper storage are real variables a buyer cannot easily verify.

Editorial verdict

ACE-031 looked genuinely effective at adding muscle in early testing, but the most important fact in its story is that its developers discontinued clinical work over safety concerns. That is not a footnote to gloss over. Any marketing that frames this as a clean, ready-to-use muscle builder is ignoring why it never reached patients.

Evidence quality

We grade the research B+. The score is weighted across 54 peer-reviewed studies, but the human side is thin: only 2 RCTs, alongside 51 animal studies and 1 review. Across the 54 classified findings, 37 supported the compound, 12 were mixed, 2 were null, and 3 refuted it. The supporting signal is real, but it leans heavily on rodent work.

What the research shows

A single ascending-dose study in healthy postmenopausal women reported statistically significant gains in total lean mass (3.3%) and thigh muscle volume (5.1%) by day 29, with a half-life of roughly 10-15 days and generally tolerable side effects. A randomized, double-blind, placebo-controlled trial in ambulatory boys with DMD was built primarily to assess safety, with efficacy as a secondary aim, dosing subcutaneously every 2-4 weeks. In mice, a 28-day course raised body weight by 16% and muscle wet weights by 26-46%, with 22-28% increases in fiber cross-sectional area in both type I and type II fibers, indicating growth that is not fiber-type selective. A review also flagged ACE-031 as a compound athletes might misuse, putting it on the radar of anti-doping programs.

Who should be cautious

Everyone, frankly. Clinical development was stopped for safety reasons in a vulnerable patient population, and there is no extended human safety record beyond short single- or multiple-dose studies. Anyone treating this as a routine bulking aid is operating well outside any tested boundary.

Dosage

Reported study dosing used single subcutaneous doses from 0.02 to 3 mg/kg, given every 2-4 weeks rather than daily. The 3 mg/kg single dose produced the largest muscle gains in healthy volunteers. Animal protocols ran 28 days; human studies tracked single-dose effects over 29 days.

Effectiveness

Measurable muscle gains appeared within 29 days of a single dose, and the effect spanned both slow- and fast-twitch fibers equally, unlike more selective myostatin blockers. Pharmacokinetic data suggested efficacy scaled with dose across the 0.02-3 mg/kg range. The decisive caveat remains that, however promising the muscle data, clinical work ended over DMD-trial safety issues.

Availability

ACE-031 is not a commercial product; its clinical development has been abandoned. It surfaces mainly in research-peptide and biohacking discussions rather than legitimate medicine. Some users point to far more expensive follistatin gene therapy (around $25k) as a more permanent alternative.

Community sentiment

Reports are extremely sparse, drawn from just 2 community submissions, with the only noted effect being increased muscle mass. There is nowhere near enough user feedback to draw conclusions.